Uncategorized

Looking for clues

One of the biggest perhaps the biggest question being asked right now is what will life look like after COVID. When it comes to healthcare everyone is wondering whether after COVID is over will patients continue to use digital health tools, i.e. virtual physician visits or will they go back to actually seeing their physician in person. Early data and it’s very early seems to indicate that while virtual visits...

This is going to work how?

There comes a point in every business when reality hits you like a ton of bricks. When it comes to diabetes Medtronic seems to have reached that point. Just as quick review after years of absolutely dominating the insulin pump market, owning formulary and bringing out innovative product offerings the company has since been leapfrogged by the competition.  The Control IQ  from Tandem now is the coolest toy in the...

It’s a new world

Since it’s Columbus Day which to us anyway celebrates the discovery of the new world it’s appropriate to examine the discovery of another new world, the post-COVID world. Yes we know COVID is still here but one day we will have a vaccine, likely several, and we will get back to whatever normal becomes. We did this after 9/11 and we’ll do it again after COVID. Just as we adapted...

You have questions, we have answers

Momma Kliff used to say never over promise and be prepared to stand by the claims you make. So in keeping with what Mom taught here are some answers to questions we have received about our upcoming  Special Report. 1. How is this report different from the many “syndicated” reports available? First we are not examining just one aspect of the diabetes market, i.e. CGM, insulin pumps, drugs etc. We are taking...

Going it alone or friends with benefits

It’s no secret that CGM is quickly becoming the standard for glucose measurement. As we have noted it won’t be long before Time in Range (TIR) joins HbA1c as a metric for measuring what is and what is not good control. While HbA1c will likely remain the de facto gold standard for non-insulin using patients, TIR combined with HbA1c will become the standard for insulin using patients. Although this metric...

MAJOR NEWS

Before we get into the news of the day some shameless self-promotion. Typically we begin the new year with back to back conferences the Consumer Electronics Show and then the JP Morgan Healthcare Conference. However as we all know there is no such thing as typical in the COVID era as both of these events have of course gone virtual. No one really knows whether ATTD scheduled for mid-February in...

Keys to the kingdom

Over the years we have seen many great ideas that never materialized into a profitable sustainable business. Our wacky world is filled with examples of way cool whiz bang devices or services which have faltered because they forgot that like it or not diabetes is not just a chronic disease but also a business. As one former device executive once said this business comes down to three critical elements; can...

Pulling the plug?

Not sure how many years it has been since all the big tech companies began their dive into the diabetes pool but whenever the official start day was we can say that this dive has been pretty much a belly flop. Years ago everyone was going gaga as Apple was developing a non-invasive continuous glucose monitor that would work with their way cool whiz bang Apple Watch. Yet Apple soon...

And the wackiness continues

One of the benefits of having been around the block more than a few times is that rarely are you surprised by any turn of events no matter how strange they appear to be on the surface. Yesterday while repenting our sins we came across a few items of interest. The first was the following; Per a post on the Fierce Pharma web site; “Novo Nordisk is partnering with the American...

Great Expectations

Yesterday when we read about the agreement between Dexcom and The University of Virginia our initial reaction was what took so long. Not to be redundant but we have consistently stated that CGM has wide ranging applications beyond diabetes. Although this agreement is diabetes focused it continues a trend that Abbott has also joined with their sensor for elite athletes. Dexcom and Abbott both understand that for sensor usage to...